Compare ETSY & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | IMVT |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.3B |
| IPO Year | N/A | N/A |
| Metric | ETSY | IMVT |
|---|---|---|
| Price | $44.57 | $26.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 27 | 9 |
| Target Price | ★ $62.29 | $30.78 |
| AVG Volume (30 Days) | ★ 3.9M | 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $24.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.05 | $12.72 |
| 52 Week High | $76.52 | $27.92 |
| Indicator | ETSY | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 27.87 | 52.23 |
| Support Level | $49.66 | $25.09 |
| Resistance Level | $58.09 | $27.92 |
| Average True Range (ATR) | 2.82 | 1.26 |
| MACD | -1.28 | -0.04 |
| Stochastic Oscillator | 2.29 | 60.78 |
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. The firm connects about 95 million buyers and 8 million sellers on its marketplace properties: Etsy and Depop (clothing resale).
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.